Canadian Journal of Neurological Sciences, published by Cambridge University Press, stands as a reputable source of knowledge in the field of neurology, dedicated to advancing research and clinical practice. With an ISSN of 0317-1671 and an E-ISSN of 2057-0155, this journal has been a cornerstone for the exchange of ideas since its inception in 1974 and will continue to cater to the academic community until 2024. Recognized in the top quartile (Q2) in various categories including Medicine (miscellaneous) and Neurology (clinical), its articles engage a broad audience, ranging from established researchers to students seeking to deepen their understanding of neurological sciences. Although the journal is not an open-access publication, it provides vital insights and research findings that contribute significantly to its fields. With a Scopus rank of #183 in clinical neurology and a percentile ranking that reflects its commendable standing, the Canadian Journal of Neurological Sciences is indispensable for those committed to the exploration and treatment of neurological disorders.

Basic and Clinical Neuroscience, published by Iran University of Medical Sciences, is a distinguished open-access journal that has been operational since 2009, providing a platform for the dissemination of significant research in the fields of neuroscience and neurology. With the ISSN 2008-126X and E-ISSN 2228-7442, this journal serves as a vital resource for researchers, clinicians, and students by facilitating access to the latest findings and advancements in cellular and molecular neuroscience as well as clinical neurology. Although currently rated in Q4 for Cellular and Molecular Neuroscience and Q3 for Clinical Neurology as of 2023, it aims to enhance its standing through the publication of high-quality, peer-reviewed research. The journal has achieved a Scopus rank placing it in the 38th percentile for Neurology and the 13th percentile for Neuroscience, indicating a growing recognition of its contributions. With its commitment to open access, Basic and Clinical Neuroscience not only contributes to the scientific community in Iran but also strives to connect researchers worldwide, fostering collaborative efforts in tackling complex neurological challenges.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, published by SAGE PUBLICATIONS INC, is a premier academic journal dedicated to advancing the understanding of mental health issues and neurological disorders in the aging population. With an established presence since 1988, this journal stands out in the fields of Geriatrics, Gerontology, Neurology, and Psychiatry, currently positioned in the Q2 category based on 2023 metrics, reflecting its influence and academic rigor. The journal is indexed in major databases and is highly regarded for its contributions, as evidenced by its strong Scopus rankings. It serves as an essential resource for researchers, clinicians, and students, offering insightful articles that explore the complex interplay between aging, mental health, and neurological conditions. Although it does not provide open access, it continues to be a vital source of scholarly knowledge for those dedicated to enhancing the well-being of the elderly population.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

The Journal of Korean Neurosurgical Society, with its ISSN 2005-3711 and E-ISSN 1598-7876, stands as a paramount resource in the field of neurosurgery, bridging clinical practice and cutting-edge research in both neurology and multidisciplinary neuroscience. Published by the Korean Neurosurgical Society, this open-access journal has been committed to disseminating invaluable knowledge to the global scientific community since its establishment in 1972. Located in Seoul, South Korea, the journal underscores its prominence with impressive quartile rankings—Q3 in Neurology (Clinical), Q3 in Neuroscience (Miscellaneous), and Q2 in Surgery for 2023. Its standing in Scopus rankings further emphasizes its impact, with a ranking of #195/551 in Medicine: Surgery and #235/400 in Medicine: Neurology (Clinical). By fostering a platform for innovative findings and advancements in surgical techniques, the Journal of Korean Neurosurgical Society aims to support professionals, researchers, and students alike in their pursuit of excellence and knowledge in neurosurgery and related fields, ensuring a brighter future for patient care and scientific inquiry.

NEUROLOGIC CLINICS, published by W B SAUNDERS CO-ELSEVIER INC, stands as a leading journal in the field of clinical neurology, boasting an impressive impact factor that reflects its significant contributions to neurological research and clinical practice. With an ISSN of 0733-8619 and E-ISSN of 1557-9875, this journal provides a critical platform for the dissemination of innovative research, case studies, and reviews focusing on various aspects of neurology, from diagnosis to treatment interventions. As part of its commitment to advancing the understanding of neurological disorders, NEUROLOGIC CLINICS is categorized in the Q2 quartile for Neurology (clinical) in 2023, indicating its robust standing within the academic community. It is recognized for its rigorous peer-review process and is indexed in Scopus, ranking #147 out of 400 in its field with a notable 63rd percentile. The journal, which dates back to 1983 and continues to publish vital findings up to 2024, is an invaluable resource for researchers, healthcare professionals, and students dedicated to enhancing their knowledge and clinical skills in neurology. Subscribe now to stay abreast of current advancements and expand your expertise in this dynamic field.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.